Cargando…

Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies

[Image: see text] An agonist–antagonist switching strategy was performed to discover novel PPARα antagonists. Phenyldiazenyl derivatives of fibrates were developed, bearing sulfonimide or amide functional groups. A second series of compounds was synthesized, replacing the phenyldiazenyl moiety with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ammazzalorso, Alessandra, Bruno, Isabella, Florio, Rosalba, De Lellis, Laura, Laghezza, Antonio, Cerchia, Carmen, De Filippis, Barbara, Fantacuzzi, Marialuigia, Giampietro, Letizia, Maccallini, Cristina, Tortorella, Paolo, Veschi, Serena, Loiodice, Fulvio, Lavecchia, Antonio, Cama, Alessandro, Amoroso, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236056/
https://www.ncbi.nlm.nih.gov/pubmed/32435362
http://dx.doi.org/10.1021/acsmedchemlett.9b00666
Descripción
Sumario:[Image: see text] An agonist–antagonist switching strategy was performed to discover novel PPARα antagonists. Phenyldiazenyl derivatives of fibrates were developed, bearing sulfonimide or amide functional groups. A second series of compounds was synthesized, replacing the phenyldiazenyl moiety with amide or urea portions. Final compounds were screened by transactivation assay, showing good PPARα antagonism and selectivity at submicromolar concentrations. When tested in cancer cell models expressing PPARα, selected derivatives induced marked effects on cell viability. Notably, 3c, 3d, and 10e displayed remarkable antiproliferative effects in two paraganglioma cell lines, with CC(50) lower than commercial PPARα antagonist GW6471 and a negligible toxicity on normal fibroblast cells. Docking studies were also performed to elucidate the binding mode of these compounds and to help interpretation of SAR data.